Denemek ALTIN - Özgür

Rise of Global MedTech Innovation in APAC

BioSpectrum Asia

|

BioSpectrum Asia Dec 2025

Asia Pacific (APAC) region has become a key global hub for MedTech innovation, shifting from a cost focused region to a centre of early commercialisation, clinical validation and scalable solutions. Reports have revealed that the share of MedTech startups, over the years, from outside the region has doubled, from 15 per cent to 30 per cent, highlighting rising global interest in APAC as a strategic entry point. This shift is primarily driven by MedTech startups from the US, the UK, and Canada. Additionally, global companies are making efforts to nurture MedTech innovations in the region. Let's take a closer look at how this trend will shape up for 2026.

- Vrushti Kothari

Rise of Global MedTech Innovation in APAC

According to reports, the APAC MedTech market is valued at $16.3 billion in 2025, with a potential to reach $18.6 billion by 2029. Reports reveal that Singapore, China, Malaysia, Thailand, Vietnam and Indonesia have emerged as the critical players of the APAC MedTech market, followed by South Korea, Japan and India.

In particular, startups within these countries are leading the way by developing innovative solutions such as AI-based diagnostics, wearables, robotic surgical instruments, digital pathology softwares etc. Moreover, these MedTech startups continue to attract investors' attention for growth and early commercialisation. In addition, new collaborations are developing between academic institutes, industry, and government across the globe for strengthening MedTech innovations in the APAC market.

“Across key APAC markets such as Singapore, Japan, South Korea, China and Australia, MedTech innovation is gaining momentum, powered by agile startups and strong public-private partnerships. There is a growing global confidence in Asia as a MedTech launchpad. India’s presence is rising, and Singapore remains a key innovation hub despite declining share”, said Fredrik Nyberg, Managing Director, MedTech Innovator Asia Pacific.

imageLooking at 2025, we see MedTech firms BD Medical Products and Terumo Asia Holdings boosting Singapore’s Duke-NUS Health Innovator Programme to strengthen the talent pipeline and accelerate commercialisation of novel MedTech solutions.

BioSpectrum Asia'den DAHA FAZLA HİKAYE

BioSpectrum Asia

BioSpectrum Asia

The Race to Build Singapore's Biotech Unicorns

MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"

As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.

time to read

4 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Leprosy Isn't Over: South-East Asia's Unfinished Fight

As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.

time to read

2 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"

After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

The Strategic Rise of India's Deep-Science Economy

India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.

time to read

4 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Japan strengthening biopharma capabilities

Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.

time to read

7 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Cancer Diagnosis, Accelerated by AI

Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.

time to read

13 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026

The oncology landscape in Asia stands at a critical juncture.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Pharma M&A set to boom in 2026

After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.

time to read

3 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Seeing Opportunity in Ophthalmology

Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.

time to read

6 mins

BioSpectrum Asia Jan 2026

Listen

Translate

Share

-
+

Change font size